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AT A GLANCE COMMENTARY 
Scientific Knowledge on the Subject 
Surgical lung biopsy for interstitial lung disease can help to clarify the diagnosis, but mortality has been 
reported to be high in some case series. 
What This Study Adds to the Field 
In a large national dataset, in-hospital mortality after elective lung biopsy was 1.7%, but significantly higher in 
non-elective procedures. Male sex, increasing age and co-morbidity were associated with increased risk.  
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In-hospital mortality following surgical lung biopsy for interstitial lung 
disease in the USA: 2000-2011 
John Hutchinson, Andrew Fogarty, Tricia McKeever, Richard Hubbard 
 
Abstract 
Rationale: Surgical lung biopsy can help to determine a specific diagnosis in interstitial lung disease, 
but has associated risks. Most currently available mortality data are derived from case series and 
may not be generalizable to broader populations.    
Objectives: We aimed to assess in-hospital mortality following surgical lung biopsy for interstitial 
lung disease in a national secondary care dataset from the United States.  
Methods: Data were obtained from the 2000-2011 Nationwide Inpatient Sample. Cases were 
identified using International Classification of Diseases (ICD-9-CM) codes for interstitial lung disease 
and surgical lung biopsies. Lung resections and cases of lung cancer were excluded. Weighted data 
were used to estimate numbers of biopsies nationwide and in-hospital mortality, and multivariable 
logistic regression was used to adjust for sex, age, geographic region, co-morbidity, type of operation 
and provisional diagnosis.  
Measurements and Main Results: We estimated there to be around 12,000 surgical lung biopsies 
performed annually for interstitial lung disease in the United States, two-thirds of which were 
performed electively. In-hospital mortality was 1.7% for elective procedures, but significantly higher 
for non-elective procedures (16.0%). Male sex, increasing age, increasing co-morbidity, open surgery 
and a provisional diagnosis of idiopathic pulmonary fibrosis or connective tissue disease related 
interstitial lung disease were risk factors for increased mortality.  
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Conclusions: In-hospital mortality following elective surgical lung biopsy for interstitial lung disease is 
just under 2%, but significantly higher for non-elective procedures. Identified risk factors for death 
should be taken into account when counselling patients on whether to pursue a histological 
diagnosis.  
Abstract word count: 248   
Keywords: interstitial lung disease, mortality, surgery 
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Introduction 
In a patient with characteristic clinical features, a confident diagnosis of idiopathic pulmonary 
fibrosis (IPF) can be made after excluding alternative causes of interstitial lung disease (ILD) and 
demonstrating typical features on high-resolution computed tomography (HRCT) of the lungs (1). In 
patients with atypical features on imaging or other cause for diagnostic uncertainty, a surgical lung 
biopsy may be required to confirm diagnosis. This may be important for management, as treatment 
options and prognosis differ greatly between the various types of ILD.  
As patients with ILD often have impaired pulmonary function, the risks of thoracic surgery are an 
important consideration when contemplating surgical lung biopsy. Several case series have explored 
morbidity and mortality following the procedure, with 30-day mortality varying from 0-24% (2, 3).  
This study aims to assess the risks of surgical lung biopsy for ILD in the United States using a national 
secondary care dataset. 
 
Methods 
We used the Nationwide Inpatient Sample (NIS), an anonymised stratified yearly sample of US 
community hospitals (4). Individual records represent discharges from hospital, and details are 
provided on diagnoses and procedures using coding based on the International Classification of 
Diseases, 9th Revision, Clinical Modification (ICD-9-CM). To preserve confidentiality, unique patient 
identifiers are unavailable. Further information on the NIS is available in the online supplement.  
We used data from 2000-2011, and selected all records with the following ICD-9-CM codes for 
interstitial lung disease: 515 (post-inflammatory pulmonary fibrosis), 516.3 (idiopathic fibrosing 
alveolitis), 517.2 (lung involvement in systemic sclerosis), 714.81 (rheumatoid lung), 517.8 (lung 
involvement in diseases classified elsewhere), 495 (extrinsic allergic alveolitis), 500-505 
(pneumoconiosis, including asbestosis) and 135 (sarcoidosis). Codes 517.2, 714.81 and 517.8 were 
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grouped together as connective tissue disease related ILD (CTD-ILD). Code 516.3 was labelled 
‘idiopathic pulmonary fibrosis clinical-syndrome’ (IPS-CS) to reflect the fact that most of these cases 
would be IPF, but some would be other idiopathic interstitial pneumonias (5). We then selected 
those hospital stays involving a surgical lung biopsy using the following ICD-9-CM procedure codes: 
33.28 (open biopsy of lung), 32.29 (other local excision or destruction of lesion or tissue of lung), 
33.20 (thoracoscopic lung biopsy) and 32.20 (thoracoscopic excision of lesion or tissue of lung) – the 
latter two codes being introduced in October 2007. We considered the ‘biopsy’ codes (33.28 and 
33.20) to be potentially more accurate than the ‘excision’ codes (32.29 and 32.20) and therefore also 
carried out a sensitivity analysis using these alone.   
We excluded records with additional codes for segmental resection, lobectomy or pneumonectomy 
that implied a therapeutic rather than diagnostic procedure. We also excluded records with a 
diagnostic code for lung cancer to ensure that diagnostic procedures for malignancy were not 
included. We focussed on procedures coded as ‘elective’ or ‘scheduled’ (as opposed to ‘non-elective’ 
– ‘urgent’ or ‘emergency’), as these would be most relevant to the clinician planning a biopsy in the 
office setting.  
We used weighted data to estimate the frequency of biopsy procedures nationwide. Our primary 
outcome measure was in-hospital mortality. We assessed risk factors for mortality using multiple 
logistic regression, adjusting for age, gender, census region, type of operation (thoracoscopic vs 
open) and co-morbidity. Co-morbidity was assessed using the updated Charlson index (6, 7): scores 
were derived from additional diagnostic codes, and matched according to published guidance (8) 
(see online supplement for further details). As the specific diagnosis in the discharge record may not 
have been the final pathological diagnosis, we presumed this to be the working or provisional 
diagnosis, and assessed its effect on mortality in our multivariable model, excluding records with 
multiple ILD diagnoses for clarity. 
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We also assessed length of stay and presence of complications. Complications were derived from 
additional diagnostic codes and therefore only assessed for elective procedures to exclude problems 
occurring prior to unplanned inpatient surgery. We limited our assessment to conditions we were 
confident were acute post-operative complications (see online for further details).  
Statistical analysis was performed using Stata, version 13.1 (StataCorp, USA). To account for the 
complex stratified sample design, estimates were calculated using the specialized survey commands, 
taking account of year and strata, and using weights to create national estimates (9). 
 
Results 
After exclusions, there were 32,022 records with a surgical lung biopsy for interstitial lung disease in 
the NIS between 2000-2011 (see Figure 1). Using weighted data, 66.3% of admissions were for 
elective procedures, 32.2% were for non-elective procedures, and for 1.5% the urgency of the 
operation was not clear. 48% of total records were male, with 61% below age 65 (Table 1: 
unweighted ‘raw’ data; Table E1A (online): weighted data). Total numbers of records by year are 
presented online (Table E1B), alongside demographics for both ‘biopsy’ and ‘excision’ codes (Tables 
E2-E3).  
After applying weightings to adjust for sampling, we estimated there to be around 12,000 surgical 
lung biopsies performed for ILD each year in the United States (see Table E4, online). Numbers were 
relatively stable over time (Figure 2), although use of ‘biopsy’ codes decreased, and ‘excision’ codes 
became more prevalent (see Table E5-E6, online).  
Biopsies were less commonly performed in the West census region (see Tables E7-9 online). The 
most commonly coded provisional diagnosis (excluding cases with more than one type of ILD coded) 
was post-inflammatory fibrosis (PIF, ICD-9-CM 515, 80% of the cohort), followed by IPF-CS (9.3%) 
and sarcoidosis (5.4%). 8.3% of records had codes for more than one type of ILD (excluded from the 
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multivariable analysis). The estimated number of biopsies for a suspected diagnosis of IPF-CS 
dropped noticeably around 2003 (Figure 3). 
 
There were 2,051 deaths recorded prior to hospital discharge in our biopsy cohort. Nationally there 
were estimated to be 9,700 deaths (95% confidence intervals (CI) 9,209-10,192) following surgical 
lung biopsy for ILD (prior to hospital discharge) between 2000 and 2011, giving an overall in-hospital 
mortality of 6.4% (95% CI 6.1%-6.7%). This comprised 1,695 deaths following elective operations 
(95% CI 1,506-1,883), giving an in-hospital mortality of 1.7% (95% CI 1.5%-1.9%), and 7,796 deaths 
following non-elective operations (95% CI 7,361-8,230), giving an in-hospital mortality of 16.0% (95% 
CI 15.2%-18.8%). In-hospital mortality reduced over time (see Table 2, Figure 4).  
Increasing mortality was associated with male sex, increasing age, higher co-morbidity scores, 
undergoing open rather than thoracoscopic surgery, and having a provisional diagnosis of IPF-CS or 
CTD-ILD (see Table 3 (elective patients), Tables E10-11 (overall and non-elective patients) – all 
weighted data). After adjusting for sex, age, co-morbidity, census region, type of operation and 
provisional diagnosis, the associations remained significant.  There were some differences between 
regions but no clear trends for both elective and non-elective procedures. Repeating the analyses for 
records with ‘biopsy’ codes only made a small difference to the overall results: mortality increased 
to 2.6% in elective patients (9.4% overall, 20.0% non-elective patients), and most of the associations 
were strengthened slightly (see Tables E12-E14 – online).  
Table 4 shows the risk of in-hospital mortality following elective surgical lung biopsy for ILD using the 
key demographic determinants of sex, age and co-morbidity level (6). Co-morbidity was classified 
into two categories: an Updated Charlson score of 0-1 (consistent with either no co-morbidity, or a 
single lower scoring condition such as chronic pulmonary disease, diabetes or renal disease), or an 
updated Charlson score 2 or greater (consistent with multiple co-morbidities, or a single higher-
scoring condition such as liver disease, dementia, heart failure, or malignancy) – further details are 
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available online. This table demonstrates the significant increase in mortality with male sex, 
increasing age and increasing co-morbidity.  
The median length of stay in our cohort of patients was 5 days, with a range of 0-308 days. 96% of 
records were for stays of 30 days or less. Excluding those remaining in hospital more than 30 days, 
in-hospital 30-day mortality was 5.4% (1.5% for elective patients, 14.2% for non-elective patients). 
Median length of stay was less for elective operations (3 days vs 12 days).  
Possible complications were estimated to occur in 30% of elective records. The most common were 
post-operative pneumothorax (8.7%), pulmonary collapse (6.4%), pneumonia (5.8%), pleural 
effusion (3.2%), respiratory failure (3.1%), other respiratory complications (encompassing ventilator-
associated pneumonia, chemical pneumonitis and transfusion-related acute lung injury) (2.0%), 
ventilator dependence (1.8%), acute kidney injury (1.7%), bleeding complications (accidental 
puncture, laceration, bleeding, haemorrhage or haematoma complicating the procedure) (1.7%),  
and surgical emphysema (1.1%).   
 
Discussion 
Our cohort of surgical lung biopsies for ILD from hospitals across the United States has shown in-
hospital mortality of just under 2% for elective operations, but a significantly increased mortality 
(16%) for non-elective (urgent and emergency) procedures. There was a strong but unsurprising link 
of mortality risk with increasing age and co-morbidity, and also associations with male sex, open 
rather than thoracoscopic surgery, and a suspected diagnosis of IPF-CS or CTD-ILD.  
The size of our cohort, at over 30,000 procedures, is the largest reported series of surgical lung 
biopsies for interstitial lung disease, and encompasses multiple centres from a large country. The NIS 
is the largest all-payer inpatient care database that is publically available in the US, including patients 
covered by Medicare, Medicaid, private insurance and the uninsured, and therefore is likely to be 
8 
 
representative of the wider patient population. We focussed on later years of the dataset (year 2000 
onwards) that were likely to have higher data completeness, with weightings used to adjust for 
sampling techniques. Although there is no universally-agreed standard for assessing co-morbidity 
using large datasets, our use of a contemporaneous score and published coding guidance helped 
ensure that our measures of co-morbidity were reliable. We identified some differences between 
regions of the US, although it is unclear whether this reflects variation in clinical practice or disease 
incidence.  
The main limitation with using the NIS was the lack of unique patient identifiers, which limited our 
ability to assess re-admissions, and raised the concern that a patient could be included more than 
once. However, it would be unusual for a patient to undergo a surgical lung biopsy on multiple 
occasions. A further limitation was the different diagnostic codes used for surgical lung biopsies, 
which in turn are dependent on clinical coders’ interpretations of operation notes, however we used 
both broader and narrower terms to assess this impact. The large difference between elective and 
non-elective procedures could be affected by incorrect coding, however it would be expected that 
more urgent cases might have higher mortality due to the severity of their illness. Our exclusion of 
records with a code for lung cancer may have excluded some biopsy patients (who are likely to have 
been higher risk) but we felt this was necessary to prevent inclusion of those undergoing biopsies for 
their cancer. It is possible that some patients with suspected malignancy but no confirmed 
diagnostic code were included in the cohort inappropriately, but it is hoped these would be a small 
group. One disadvantage of using discharge records compared to a case series was the lack of a 
definitive histological diagnosis, and the popularity of the non-specific ICD-9-CM code for post-
inflammatory fibrosis – a condition not widely recognised in updated guidelines – limited our ability 
to assess the impact of the type of ILD.  
We were unable to assess 30-day or 90-day mortality, measures commonly used in other case series, 
and since the vast majority of our patients were discharged within 30 days it is likely that 30-day 
9 
 
mortality would be slightly higher than our estimate, to account for deaths at home and after re-
admissions. Our analysis of co-morbidity codes was only able to include those mentioned on the 
admission record, and it is possible that having a longer baseline period would have captured further 
conditions – thereby putting patients into higher risk co-morbidity categories, and potentially 
lowering the mortality risk associated with higher co-morbidity – however it would be hoped that 
the more significant co-morbidities coded with the updated Charlson score would be highlighted on 
an inpatient admission. Finally, we lacked reliable data on medications such as corticosteroids, 
immunosuppression, anticoagulation and pre-operative oxygen requirements, all of which have 
been associated with adverse outcomes in surgical lung biopsy case series (10-12), and these should 
clearly be taken into account when counselling patients on risk. Nevertheless, our risk table (Table 6) 
gives a reasonable estimate of surgical risk that may be useful in the pre-operative consultation. The 
possibility that this may underestimate the true risks (due to exclusion of some higher risk patients 
and those dying after hospital discharge, and misclassification of some patients as ‘non-elective’) 
should be kept in mind.  
We systematically reviewed the literature for studies reporting mortality after surgical lung biopsy 
for interstitial lung disease, and identified over 50 reports from at least 20 countries. Differences in 
research aims, case selection (IPF vs any ILD), type of surgery (open vs thoracoscopic) and reporting 
outcomes (30 day mortality vs ‘post-operative’ or other) limited comparison between studies, but 
mortality estimates ranged from 0-34%. Studies reporting higher mortality tended to highlight the 
presence of acute symptoms, older age, pre-operative respiratory failure or mechanical ventilation, 
and immunosuppression as associated with poor outcomes (3, 13-17), suggesting more careful case 
selection could improve outcomes. Supporting this, one US study specifically of patients undergoing 
biopsy during an acute exacerbation showed survival in only 1 of 7 patients (18). Few studies 
distinguished between elective and non-elective surgery, although many included patients who were 
acutely unwell and likely to have undergone an urgent procedure.  
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Our estimate of 1.7% for in-hospital mortality following elective surgery is comparable with other 
estimates. Nguyen and Meyer (19) quoted ‘overall mortality’ of 3.5% in their recent comprehensive 
review of studies (2.1% mortality for thoracoscopic surgery, 4.3% for open), although it was unclear 
how many of these were elective procedures. Kreider et al reviewed previous studies in 2007, and 
derived a composite postoperative mortality of 4.5% (10), noting a significantly increased mortality 
of 47% in those requiring pre-operative ventilation compared to 2.2% in those free from ventilation. 
Overall, our data supports the far higher risk of surgery in unplanned procedures. The fact that one 
in three patients in our dataset underwent a non-elective procedure suggests that these higher risk 
procedures are still being performed regularly. While it is impossible to state the contribution of the 
surgery itself towards post-operative death, in a cohort who are clearly unwell due to underlying 
lung disease, patients should be aware of the mortality of those undergoing surgery in these 
circumstances. The decrease in procedures for suspected IPF-CS after 2003 likely reflects the 
publication of American Thoracic Society (ATS) guidelines clarifying the diagnostic criteria for IPF and 
suggesting biopsy is not needed in those with typical radiological appearances (20). 
The overall incidence of ILD in the US is not clear, but studies of conditions such as rheumatoid-
arthritis associated ILD and sarcoidosis suggest it is increasing (21, 22). Most data surrounds IPF, 
which seems to be increasing worldwide (23), although perhaps less so recently in the US (24, 25), 
which may reflect fewer patients meeting strict ATS criteria, and an increasing number with 
‘unclassified’ ILD. It is possible that the stable absolute number of surgical lung biopsies performed 
over time reflects decreasing utilization of the procedure in an increasing number of ILD patients, 
who are being diagnosed more commonly using radiology and multi-disciplinary meetings.  
In conclusion, our data suggests that surgical lung biopsy for interstitial lung disease is associated 
with in-hospital mortality of 1.7% in elective patients, but a significantly increased mortality of 
greater than 15% in unplanned procedures. Increasing age and co-morbidity were the main risk 
factors for mortality, but male sex, open surgery and a provisional diagnosis of IPF-CS or CTD-ILD 
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were also associated. Clinicians should make patients aware of the high risk nature of non-elective 
surgical biopsy for ILD, and tailor their advice to individual clinical risk profiles.  
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Figure Legends 
 
Figure 1: Flow diagram of selection process for records with a surgical lung biopsy for interstitial lung 
disease. 
 
Figure 2: Estimated number of surgical lung biopsies nationwide for interstitial lung disease. 
 
Figure 3: Estimated number of surgical lung biopsies nationwide for a suspected diagnosis of 
idiopathic pulmonary fibrosis clinical-syndrome (ICD-9-CM code 516.3). 
 
Figure 4: In-hospital mortality following surgical lung biopsy for the diagnosis of interstitial lung 
disease. 
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Tables 
Table 1: Demographics of biopsy cohort (unweighted data) 
  Total admissions 
(n=32,022) 
Elective admissions 
(n=21,227) 
Non-elective 
admissions 
(n=10,310) 
  Number (%) Number (%) Number (%) 
Sex 
 Male 15,351 (47.94) 9,942 (46.84) 5,163 (50.08) 
 Female 16,671 (52.06) 11,285 (53.16) 5,147 (49.92) 
Age group (years) 
 <45 5,192 (16.21) 3,153 (14.85) 1,958 (18.99) 
 45-54 6,264 (19.56) 4,229 (19.92) 1,944 (18.86) 
 55-64 8,093 (25.27) 5,643(26.58) 2,331 (22.61) 
 65-74 8,147 (25.44) 5,623 (26.58) 2,406 (23.34) 
 75-84 4,037 (12.61) 2,431 (11.45) 1,535 (14.89) 
 >84 289 (0.90) 148 (0.70) 136 (1.32) 
Level of co-morbidity (Updated Charlson score) 
 0 13,908 (43.43) 10,627 (50.06) 3,030 (29.39) 
 1 10,844 (33.86) 7,158 (33.72) 3,558 (34.51) 
 2 3,304 (10.32) 1,728 (8.14) 1,523 (14.77) 
 3 or greater 3,966 (12.39) 1,714 (8.07) 2,199 (21.33) 
Higher Updated Charlson score = greater co-morbidity.  
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Table 2: In-hospital mortality following surgical lung biopsy for interstitial lung disease, by year 
Year of biopsy 
Total admissions Elective admissions Non-elective 
admissions 
Deaths (% mortality) Deaths (% mortality) Deaths (% mortality) 
2000 822 (7.6) 120 (1.2) 591 (16.6) 
2001 962 (7.5) 173 (2.2) 690 (17.6) 
2002 923 (6.9) 196 (2.1) 727 (17.5) 
2003 934 (7.3) 173 (2.1) 761 (17.6) 
2004 875 (7.0) 131 (1.6) 745 (18.8) 
2005 876 (6.6) 148 (1.7) 727 (16.6) 
2006 876 (6.6) 139 (1.6) 736 (16.5) 
2007 696 (5.4) 116 (1.3) 580 (14.1) 
2008 715 (5.8) 135 (1.6) 580 (15.0) 
2009 709 (5.5) 123 (1.5) 586 (13.2) 
2010 696 (5.7) 139 (1.7) 557 (14.3) 
2011 617 (4.9) 101 (1.2) 516 (13.5) 
Total 9700 (6.4) 1695 (1.7) 7796 (16.0) 
Deaths estimates rounded to nearest integer. Totals calculated using raw data rather than sum of 
rounded values. 
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Table 3: Multivariable analysis – associations with in-hospital death after surgical lung biopsy – 
elective procedures 
 
Variables Cases Deaths (%) Unadjusted OR 
(95% CI) 
p value Adjusted OR 
(95% CI) 
p value 
Sex 
 Female 53,552 733 (1.4) 1.00  1.00  
 Male 47,147 962 (2.0) 1.50 (1.22-1.85) <0.001 1.41 (1.14-1.76) 0.002 
Age (years) 
 <45 14,985 95 (0.6) 1.00 <0.001 
(p for 
trend) 
1.00 <0.001 
(p for 
trend) 
 45-54 20,073 148 (0.7) 1.16 (0.67-2.01) 1.20 (0.68-2.12) 
 55-64 26,680 393 (1.5) 2.33 (1.42-3.83) 2.00 (1.19-3.38) 
 65-74 26,702 611 (2.3) 3.66 (2.28-5.88) 3.09 (1.87-5.09) 
 75-84 11,547 418 (3.6) 5.86 (3.63-9.47) 4.46 (2.69-7.40) 
 >84 711 29 (4.0) 6.56 (2.58-16.65) 5.25 (2.16-12.74) 
Updated Charlson score 
 0 50,389 410 (0.8) 1.00 <0.001 
(p for 
trend) 
1.00 <0.001 
(p for 
trend) 
 1 33,949 509 (1.5) 1.86 (1.41-2.45) 1.83 (1.38-2.43) 
 2 8,222 359 (4.4) 5.56 (4.09-7.56) 5.17 (3.75-7.14) 
 3 or more 8,139 417 (5.1) 6.58 (4.83-8.96) 5.95 (4.32-8.20) 
Geographical region 
 South 35,345 716 (2.0) 1.00  1.00  
 Northeast 22,108 234 (1.1) 0.52 (0.37-0.73) <0.001 0.53 (0.37-0.76) 0.001 
 Midwest 26,824 492 (1.8) 0.91 (0.69-1.19) 0.477 0.94 (0.71-1.25) 0.668 
 West 16,421 252 (1.5) 0.75 (0.55-1.03) 0.076 0.75 (0.54-1.04) 0.083 
Year group       
 2000-2002 23,311 490 (2.1) 1.00 0.009 
(p for 
trend) 
1.00 0.028 
(p for 
trend) 
 2003-2005 25,719 452 (1.8) 0.83 (0.62-1.12) 0.83 (0.61-1.14) 
 2006-2008 26,163 391 (1.5) 0.71 (0.53-0.95) 0.76 (0.56-1.05) 
 2009-2011 25,505 362 (1.4) 0.67 (0.49-0.93) 0.67 (0.47-0.95) 
Type of operation (post-October 2007 patients only) 
 VATS 26,647 314 (1.2) 1.00  - - 
 Open 9,511 218 (2.3) 1.96 (1.36-2.83) <0.001 - - 
Provisional diagnosis (patients with single ILD diagnostic code only) 
 PIF 79,853 1,143 (1.4) 1.00  1.00  
 IPF-CS 7,303 374 (5.1) 3.71 (2.83-4.88) <0.001 3.17 (2.36-4.26) <0.001 
 CTD-ILD 1,111 67 (6.0) 4.39 (2.52-7.64) <0.001 2.93 (1.65-5.22) <0.001 
 Sarcoid 5,270 15 (0.3) 0.19 (0.06-0.59) 0.004 0.28 (0.09-0.89) 0.031 
 Other 3,148 14 (0.5) 0.32 (0.10-1.00) 0.050 0.19 (0.06-0.61) 0.005 
Multivariable analysis excludes type of operation due to lower numbers; type of operation remained 
significant if included. 
Higher Updated Charlson score reflects greater degree of co-morbidity. 
Estimated numbers of cases and deaths rounded to nearest integer.  
VATS: video-assisted thoracoscopic surgery. OR: Odds Ratio; 95% CI: 95% confidence interval. 
PIF: post-inflammatory fibrosis; IPF-CS: idiopathic pulmonary fibrosis clinical-syndrome; CTD-ILD: connective 
tissue disease related interstitial lung disease; ‘Other’: hypersensitivity pneumonitis and pneumoconioses 
(including asbestosis) – grouped due to smaller numbers. 
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Table 4: Risk of in-hospital mortality (percent (95% confidence intervals)) following elective 
surgical lung biopsy for interstitial lung disease, by age and co-morbidity.  
  
Age <55 years 
 
Age 55-74 years Age > 74 years 
MALES 
 
Updated Charlson 
score: 0-1 
 
0.4% 
(0.19-0.67) 
1.5% 
(1.20-1.92) 
2.7% 
(1.82-3.86) 
 
Updated Charlson 
score: 2 or greater 
 
3.7% 
(2.29-6.06) 
5.4% 
(4.02-7.12) 
10.1% 
(7.33-13.87) 
FEMALES 
 
Updated Charlson 
score: 0-1 
 
0.4% 
(0.25-0.70) 
1.1% 
(0.87-1.48) 
1.9% 
(1.21-2.94) 
 
Updated Charlson 
score: 2 or greater 
 
1.9% 
(1.00-3.46) 
4.0% 
(2.95-5.48) 
5.7% 
(3.36-9.51) 
Updated Charlson score from Quan H et al. Updating and Validating the Charlson Comorbidity Index 
and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data from 6 Countries. Am J 
Epidemiol  2011; 173: 676-682 
For information on how to calculate the updated Charlson score, see Figure E1 in the online 
supplement.  
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Figures 
Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
871,401 discharge records 
with diagnostic code for 
interstitial lung disease 
34,530 with procedure code 
for surgical lung biopsy 
16,622 ‘biopsy’ codes 
18,533 ‘excision’ codes 
32,022 records for analysis 
353 exclusions due to codes 
for lung resection  
2,104 additional exclusions 
due to codes for lung cancer 
51 additional exclusions due 
to no sex indicator 
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Figure 4 
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